期刊
CANCER GENOMICS & PROTEOMICS
卷 18, 期 3, 页码 369-383出版社
INT INST ANTICANCER RESEARCH
DOI: 10.21873/cgp.20266
关键词
Circulating tumor DNA; circulating tumor cells; exosomes; liquid biopsy; hepatocellular carcinoma; personalized medicine; review
资金
- I.M. Sechenov First Moscow State Medical University Strategic Development Program under the Russian Academic Excellence Project 5-100
Liquid biopsy is a novel, minimally invasive approach for monitoring tumor progression, metastasis, and recurrence in hepatocellular carcinoma (HCC), but it presents a risk of bias in early detection due to its relatively high specificity and low sensitivity. Next-generation sequencing technologies offer accurate and comprehensive analysis of gene expression and mutational profiling in liquid biopsies, potentially enhancing precision oncology capabilities in HCC patients with varying genomic signatures.
Hepatocellular carcinoma (HCC) is the sixth most frequently diagnosed cancer and the third leading cause of cancer-related deaths worldwide. Advanced-stage HCC patients have poor survival rates and this requires the discovery of novel clear biomarkers for HCC early diagnosis and prognosis, identifying risk factors, distinguishing HCC from non-HCC liver diseases, and assessment of treatment response. Liquid biopsy has emerged as a novel minimally invasive approach to enable monitoring tumor progression, metastasis, and recurrence. Since the liquid biopsy analysis has relatively high specificity and low sensitivity in cancer early detection, there is a risk of bias. Next-generation sequencing (NGS) technologies provide accurate and comprehensive gene expression and mutational profiling of liquid biopsies including cell-free circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and genomic components of extracellular vesicles (EVs) including microRNAs ( miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs). Since HCC is a highly heterogeneous cancer, HCC patients can display various genomic, epigenomic, and transcriptomic patterns and exhibit varying sensitivity to treatment options. Identification of individual variabilities in genomic signatures in liquid biopsy has the potential to greatly enhance precision oncology capabilities. In this review, we highlight and critically discuss the latest progress in characterizing the genomic landscape of liquid biopsy, which can advance HCC personalized medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据